Non-alcoholic Steatohepatitis Biomarkers Market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%

Non-alcoholic steatohepatitis is a progressive phase of non-alcoholic fatty liver disease (NAFLD), which is caused due to the excess fat accumulation leading to inflammation and damage resulting to liver scarring. NASH biomarkers are used as diagnostic tools to measure the severity of non-alcoholic steatohepatitis and for the liver damage assessment. Emerging advancements in technology in biomarker identification for NASH is supporting in the NASH biomarker development.

The report "Global Non-alcoholic Steatohepatitis Biomarkers Market, By Type (Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers, and Others), By End-user (Pharma & CRO Industry, Hospitals, Diagnostic Labs, and Academic Research Institutes), and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029”.

Key Highlights:

  • In January 2019, LabCorp. a leading global life sciences company, and GENFIT, a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver-related diseases, announced the signing of a licensing agreement between GENFIT and Covance, LabCorp's drug development business. The agreement will expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.
  • In November 2019, Novartis announced positive interim results from the final part of its phase IIb FLIGHT-FXR adaptive design study, assessing the safety, tolerability, and efficacy of tropifexor in patients with biopsy-confirmed stage 2-3 fibrotic non-alcoholic steatohepatitis (NASH).

Analyst View:

The prevalence rate of non-alcoholic liver diseases has grown significantly. Patients with obesity and type 2 diabetes are projected to be more susceptible to NAFLD and other liver diseases. This is projected to drive the prevalence of non-alcoholic liver diseases. High pollution levels and changes in lifestyle are expected to propel the prevalence of nonalcoholic liver diseases. This, in turn, is anticipated to propel the NASH biomarkers market over the forecast period.

The biopharmaceutical company named “GENFIT” has undertaken an initiative for NASH Education Program in 2016. It’s a public health initiative aimed to create awareness about NASH among patients. These types of programs are measured to expedite utilization of NASH therapeutics. Moreover, GENFIT started Pediatric NAFLD/NASH Program in Europe after approval of elafibranor’s Pediatric Investigation Plan by the European Medicine Agency, which is further expected to ease the drug development program in the future.

Key Market Insights from the report:        

The global non-alcoholic steatohepatitis biomarkers market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated to register a CAGR of 31.3%. The market report has been segmented on the basis of type, end-user, and region.

  • By type, serum biomarkers type segment accounted dominant share as of 2019. Serum biomarkers are the most commonly used diagnostic tools for detection of NASH. Moreover, the introduction of emerging products, such ghrelin & tumor necrosis factor-alpha, asleptin, free fatty acids, apolipoprotein B, apolipoprotein A1, and adiponectin that can provide valuable services complementary to the traditional ones is expected to drive the segment growth.
  • By end-user, pharmaceutical industry and contract research organizations (CROs) accounted for a dominant share as of 2019. Growing demand for noninvasive NASH diagnostic & monitoring tools by CROs and pharmaceutical manufacturers in the ongoing clinical trials can be attributed to its robust growth. This segment is projected to register a lucrative growth rate in the upcoming years.
  • By region, North America is expected to account the dominating position in the non-alcoholic steatohepatitis (NASH) biomarkers market in the upcoming years. Driving government initiatives, the presence of sophisticated healthcare amenities, and the growing incidence of diabetes, obesity, and fatty liver disease is supporting the growth of the target market in this region.

Before purchasing this report, request a sample or make an inquiry by clicking the following link:

https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/4413

Competitive Landscape:

The prominent player operating in the global non-alcoholic steatohepatitis biomarkers market includes GENFIT, Gilead, AstraZeneca, Novartis AG, GE Healthcare, EUSA Pharma, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Allergan Novo Nordisk A/S, and Pfizer, Inc.

The market provides detailed information regarding the industrial base, productivity, strengths, manufacturers, and recent trends which will help companies enlarge the businesses and promote financial growth. Furthermore, the report exhibits dynamic factors including segments, sub-segments, regional marketplaces, competition, dominant key players, and market forecasts. In addition, the market includes recent collaborations, mergers, acquisitions, and partnerships along with regulatory frameworks across different regions impacting the market trajectory. Recent technological advances and innovations influencing the global market are included in the report.

About Prophecy Market Insights

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Sales

+1 860 531 2701

Email- sales@prophecymarketinsights.com

Comments

Post a Comment

Popular posts from this blog

Global Platelet Rich Plasma Market is estimated to be US$ 1003.06 million by 2030 with a CAGR of 11.50% during the forecast period.

Image
Global Platelet Rich Plasma Market accounted for US$ 337.23 million in 2020 and is estimated to be US$ 1003.06 million by 2030 and is anticipated to register a CAGR of 11.50%. Platelet-rich plasma (PRP), also known as autologous conditioned plasma, is created by extracting red blood cells from blood. When the concentration of platelets in human blood is reduced, platelet-rich plasma is separated, which contains a concentration of platelets above typical values. Platelets thicken the blood and aid in the repair of muscles, ligaments, and tendons. They are extremely high in healing and connective tissue development factors. Platelet-rich plasma (PRP) blends the body's natural ability to heal itself with modern technologies. It has a wide range of medical applications, including neurology, orthopaedics, and ophthalmology. It's also employed in procedures like tendon repair and rotator cuff augmentation. The report   " Global Platelet Rich Plasma Market, By Type (Pure Platelet...
Read more

Neurodegenerative Disorder Therapeutics Market - Improvement in the healthcare infrastructure is likely to create new opportunity for the market

Image
Neurodegenerative Disorder Therapeutics Market   accounted for US$ 9.32 billion in 2019 and is estimated to be US$ 21.3 billion by 2029 and is anticipated to register a CAGR of 8.7% The report " Global  Neurodegenerative Disorder Therapeutics Market, By  Indication Type (Parkinson's Disease, Alzheimer's Disease, Multiple Sclerosis, Huntington Disease, and Other Indication Types), By Drug Type (N- methyl- D- aspartate Receptor, Selective Serotonin Reuptake Inhibitor, Dopamine Inhibitors, and Other Drug Types), By Distribution (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy),  and By Region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa) - Trends, Analysis and Forecast till 2029” . Key Highlights: In November 2019, Alkermes plc and Rodin Therapeutics, Inc. announced that they have entered into a definitive agreement under which Alkermes will acquire Rodin, a privately held biopharmaceutical company focused ...
Read more

Systemic Lupus Erythematosus Market accounted for US$ 1.87 billion in 2019 and is estimated to be US$ 3.6 billion by 2029 and is anticipated to register a CAGR of 7.0%

Image
  Systemic Lupus Erythematosus (SLE) is the chronic, autoimmune disorder which involves several organ-systems such as kidney, heart, blood, skin, joints, and lungs in most severe cases, brain. In this disease, the human immune system converts hyperactive and attacks the healthy, normal tissues of the body. SLE can often result in symptoms such as malar rash, sub-acute cutaneous lesions, discoid lesions, arthritis, photosensitivity, oral ulcers, serositis, nephropathy, thrombocytopenia, haemolytic anemia, neurologic involvement, fever, thrombosis, Raynaud’s phenomenon, livedo reticularis, and myositis. The global systemic lupus erythematosus market accounted for US$ 1.87 billion in 2019 and is estimated to be US$ 3.6 billion by 2029 and is anticipated to register a CAGR of 7.0%. The report  " Global   Systemic Lupus Erythematosus Market, By Drug Classes (NSAIDs, Corticosteroids, Antimalarials, Immunosuppressants, and Biologics), By Route of Administration (Oral, In...
Read more